AKT1 and esophageal squamous cell carcinoma: Our study first demonstrated that anlotinib combined with raltitrexed produced significant inhibition on cell proliferation, migration, and invasion in ESCC cell lines KYSE-30 and TE-1 by down-regulating the expression of p-Akt and p-Erk.